Pfizer is enlisting the power of pictures for its next chapter in its metastatic breast cancer awareness campaign. For "Story Half Told," the pharma has hired 5 prominent Instagram photographers to chronicle the everyday lives of women living with MBC.
Researchers at the University of Pennsylvania Perelman School of Medicine found that the interplay between a well-known tumor suppressor molecule and an oncogene may explain why breast cancer patients become resistant to Tykerb (lapatinib).
Eli Lilly's would-be rival to Pfizer's Ibrance (palbociclib) just gained an inside track at the FDA. Regulators handed Lilly the coveted "breakthrough therapy" designation for abemaciclib, another CDK 4/6 inhibitor with big plans for carving out a niche among patients with advanced breast cancer.
Evgen Pharma has rebooted its IPO plans months after abandoning an attempt to raise £20 million ($30 million) on the London Stock Exchange. The aim now is to tap investors for £5 million, a sum that will support Phase II trials of Evgen's vegetable-inspired drug in breast cancer and stroke.
As medical experts question the efficacy of mammograms in breast cancer screening, a new study shows that computer-aided detection technology used during the process does not help spot cancer in patients.
Startup Delphinus Medical Technologies has raised $39.5 million to support a pivotal trial of its ultrasound breast cancer system, SoftVue. The system enables the imaging of the entire breast including the chest wall and is expected to be more effective at identifying tumors in dense breasts--without creating a high false positive rate.
Researchers have long searched for ways to track cancer cells as they proliferate and stop them from spreading. Now, scientists in the U.S. are developing a spongelike device that can mop up cancer cells as they move through the body, potentially offering an early warning sign to doctors.
The oncology community is divided over intraoperative radiation therapy, which as its name suggests is given at the same time as lumpectomy to breast cancer patients.
As med tech companies roll out innovative radiation devices to treat breast cancer, medical experts are debating the pros and cons of a new technique that could be less expensive and more convenient than traditional therapy for the disease.
Scientists at Nottingham Trent University, Nottingham University Hospitals NHS Trust and the University of Nottingham have identified a possible target for triple negative breast cancers, offering vaccine makers a potential path forward against the cancer and patients hope where other treatments have failed.